Table 4.

Glucose metabolism by group

CharacteristicHS (n=82)Het (n=81)GS (n=77)ANOVA P Value
Antidiabetic drugs064
Insulin020
Metformin/sulfamides0/05/22/0
DPP4 inhibitors021
Hypolipemiant treatment
 Statins/fibrates0/010/98/6
Plasma
 Glucose T0, mM4.8 [4.7; 5.2]5.0 [4.6; 5.4]5.1 [4.8; 5.5]0.01
 Glucose T120, mM5.3 [4.6; 5.9]a5.4 [4.7; 6.1]a6.2 [5.5; 7.1]<0.001
 Change in glucose (T120–T0)0.50 [-0.10; 1.20]b0.40 [-0.30; 1.20]b1.10 [0.30; 1.80]<0.001
 Insulin T0, mUI/l4.4 [3.1; 5.4]a4.4 [3.2; 7.3]b6.8 [4.3; 10.8]<0.001
 Insulin T120, mUI/l15.9 [8.6; 26.2]a22.0 [10.4; 35.9]b28.6 [17.8; 47.7]<0.001
 Change in insulin (T120–T0)11.1 [5.8; 21.7]a18.0 [7.4; 32.1]21.3 [11.7; 41.0]<0.001
  QUICKI T00.38 [0.37; 0.40]a0.38 [0.35; 0.41]b0.35 [0.33; 0.39]<0.001
  IR index T00.50 [0.38; 0.60]a0.51 [0.39; 0.80]a0.77 [0.48; 1.22]<0.001
 Cholesterol, mM5.09 [4.27; 5.63]4.98 [4.37; 5.67]5.27 [4.63; 6.01]0.1
 HDL cholesterol, mM1.36 [1.18; 1.58]1.48 [1.23; 1.70]1.45 [1.13; 1.66]0.10
 LDL cholesterol, mM3.07 [2.56; 3.67]3.01 [2.44; 3.72]3.34 [2.80; 3.92]0.23
 Triglycerides, mM1.00 [0.71; 1.43]1.00 [0.72; 1.33]1.10 [0.83; 1.60]0.11
 ALAT, UI/L17 [14; 24]a18 [13; 23]a23 [17; 39]<0.001
 ASAT, UI/L16 [12; 19]a17 [13; 22]a21 [17; 30]<0.001
 GGT, UI/L24 [14; 33]20 [14; 28]24 [16; 43]0.27
 ALP, UI/L55 [44; 64]56 [47; 63]51 [42; 61]0.10
  • Data are presented as median [IQR]. ANOVA was performed to compare Het or HS versus patients with GS. If significant, Tukey or Dunn test was performed to compare HS and Het and HS or Het versus GS (a,b,c). T0, before glucose load; T120, after glucose load; ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase; GGT, gamma-glutamyl transferase; ALP, alkalin phosphaphatase.

  • a P<0.001.

  • b P<0.05.